CORC

浏览/检索结果: 共2条,第1-2条 帮助

限定条件                
已选(0)清除 条数/页:   排序方式:
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions 期刊论文
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 卷号: 68, 期号: 3
作者:  Zi, Zhenguo;  Jin, Yanling;  Li, Gaoxin;  Shao, Kang;  Cai, Qiliang
收藏  |  浏览/下载:19/0  |  提交时间:2019/12/05
Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress 会议论文
作者:  Ren, Z.;  Assenat, E.;  Cubillo, A.;  Pluntke, S.;  Rimassa, L.
收藏  |  浏览/下载:11/0  |  提交时间:2019/12/05


©版权所有 ©2017 CSpace - Powered by CSpace